Back to top
more

Baxter International (BAX)

(Delayed Data from NYSE)

$23.54 USD

23.54
12,327,695

+1.04 (4.62%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $23.53 -0.01 (-0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (156 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Headquartered in Deerfield, IL, Baxter International Inc. (BAX) is a global medical technology company. However, the company spun off its biopharmaceuticals segment into an independent entity – Baxalta Inc. Following the spinoff, the company consists of renal and hospital products, providing items such as kidney-dialysis equipment, infusion pumps, and intravenous (IV) solutions.

Zacks Equity Research

NextGen's (NXGN) Integrated Platform to Enhance Tribal Health

by Zacks Equity Research

NextGen's (NXGN) integrated platform was adopted by a community health center in Northern California to meet the health requirements of American Indians/Alaska Natives.

Zacks Equity Research

CVS Health (CVS) Hits a 52-Week High: What's Driving It?

by Zacks Equity Research

Strength across the retail segment and growing specialty pharmacy revenues are driving CVS Health's (CVS) top line.

Zacks Equity Research

Thermo Fisher (TMO) Base Sales Rebound, Bioproduction in Focus

by Zacks Equity Research

Thermo Fisher (TMO) is currently expanding its bioproduction purification resin capacity, which is used in the mRNA manufacturing process.

Zacks Equity Research

Here's Why You Should Invest in Henry Schein (HSIC) Now

by Zacks Equity Research

Investors are optimistic about Henry Schein's (HSIC) strong segmental performance and raised 2021 EPS guidance.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Roche Holding, Pfizer, Baxter International, STMicro and Philips

by Zacks Equity Research

Roche Holding, Pfizer, Baxter International, STMicro and Philips are included in this analyst blog.

Zacks Equity Research

Veeva Systems (VEEV)-LYSARC Partner to Advance Lymphoma Therapy

by Zacks Equity Research

Veeva Systems' (VEEV) Veeva Development Cloud will allow LYSARC to develop innovative lymphoma therapies or enhance current therapies.

John Blank headshot

Oxygen from Earnings: Global Week Ahead

by John Blank

In the Global Week Ahead, Q4 S&P500 earnings will supply the latest details on how major global companies are dealing with rising wage cost pressures.

Zacks Equity Research

Medtronic (MDT) Undertakes Investment to Advance STEM Education

by Zacks Equity Research

The Medtronic Foundation, solely funded by Medtronic plc (MDT), entered into 13 new partnerships to bridge the inequity in STEM education among underrepresented and underserved communities.

Zacks Equity Research

Catalent (CTLT) to Advance Oral Drug Development With New Launch

by Zacks Equity Research

Catalent's (CTLT) Xpress Pharmaceutics service offers a quicker alternative to the traditional clinical development model, lowering the time needed to complete clinical studies.

Zacks Equity Research

Here's Why You Should Retain Chemed (CHE) Stock for Now

by Zacks Equity Research

Investors are optimistic about Chemed (CHE), given impressive performance of the Roto-Rooter arm and solid growth in VITAS admissions.

Zacks Equity Research

Abiomed (ABMD) Reports Positive Data Backing preCARDIA System

by Zacks Equity Research

Abiomed's (ABMD) preCARDIA system has proven to be effective in reducing cardiac filling pressures and increasing urine output in ADHF patients.

Zacks Equity Research

Is ATI Physical Therapy, Inc. (ATIP) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how ATI Physical Therapy, Inc. (ATIP) and Baxter International (BAX) have performed compared to their sector so far this year.

Zacks Equity Research

New Strong Buy Stocks for January 18th

by Zacks Equity Research

KBH, BAX, F, EGO, and AXS have been added to the Zacks Rank #1 (Strong Buy) List on January 18, 2022.

Zacks Equity Research

PacBio (PACB) to Leverage Google's Deep Learning Technologies

by Zacks Equity Research

PacBio's (PACB) research collaboration with Google will likely enhance its HiFi Sequencing technology to extract greater value from genomic data.

Zacks Equity Research

Here's Why You Should Invest in Neogen (NEOG) Stock Now

by Zacks Equity Research

Neogen's (NEOG) better-than-expected Q2 revenues and robust growth across Food Safety & Animal Safety businesses instill investor confidence.

Zacks Equity Research

Best Momentum Stocks to Buy for January 18th

by Zacks Equity Research

BAX, F, and EGO made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 18, 2022

Zacks Equity Research

Best Income Stocks to Buy for January 18th

by Zacks Equity Research

BAX, F, and WBS made it to the Zacks Rank #1 (Strong Buy) income stocks list on January 18, 2022

Nalak Das headshot

5 Low-Beta High-Yielding Stocks to Buy in a Capricious Market

by Nalak Das

We have narrowed our search to five large-cap low-beta stocks with a solid dividend yield. These are: PFE, BAX, IBKR, PSA and CUBE.

Zacks Equity Research

Cardiovascular Systems (CSII) Expands Lithotripsy Technology

by Zacks Equity Research

Cardiovascular Systems (CSII) has developed intravascular lithotripsy systems to treat calcific coronary and peripheral artery diseases.

Zacks Equity Research

New Strong Buy Stocks for January 17th

by Zacks Equity Research

AXS, BAX, F, UNFI, and BRDG have been added to the Zacks Rank #1 (Strong Buy) List on January 17, 2022.

Zacks Equity Research

Here's Why You Should Retain Baxter (BAX) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Baxter (BAX) due to its strong product portfolio.

Debanjana Dey headshot

4 Stocks to Watch Out For as MedTech Rides on Buyout Frenzy

by Debanjana Dey

Here are some MedTech stocks - Quidel (QDEL), Thermo Fisher (TMO), Baxter (BAX) and BD (BDX) - that have been quite active in the acquisition front and therefore worth investor attention.

Zacks Equity Research

Here's Why You Should Retain Baxter (BAX) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Baxter (BAX) due to its strong product portfolio.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Abbott Laboratories, West Pharmaceuticals Services, Baxter International and Chemed Corp

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Abbott Laboratories, West Pharmaceuticals Services, Baxter International and Chemed Corp

Riya Anand headshot

4 MedTech Dividend Stocks in Focus on Amid Omicron Variant Panic

by Riya Anand

Abbott Laboratories (ABT), West Pharmaceuticals Services (WST), Baxter International (BAX) and Chemed Corporation (CHE) are high-yield dividend stocks with sustainable business models.